EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)Randomisierte kontrollierte StudieVergleichsstudieOpen Access

Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial

Hidenori Arai, Shizuya Yamashita, Eiichi Araki, Koutaro Yokote, Ryohei Tanigawa, Ayumi Saito, Sayumi Yamasaki, Hideki Suganami, Shun Ishibashi

Journal of Atherosclerosis and Thrombosis · 2024

DOI: 10.5551/jat.64677 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Atherosclerosis and Thrombosis, 2024. Verfasst von Hidenori Arai und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Geriatrics and Gerontology. Hauptthemen laut MEDLINE: Benzoxazoles, Delayed-Action Preparations, Hypertriglyceridemia, Triglycerides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazolesDelayed-Action PreparationsHypertriglyceridemiaTriglyceridesButyratesHumansMaleDouble-Blind MethodFemaleMiddle AgedTabletsAgedHypolipidemic AgentsAdultTreatment OutcomePhenylalanine

Stichwörter der Autor:innen

Extended releasePemafibrateRemnantsSelective PPARα modulatorTriglycerides

Substanzen

BenzoxazolesDelayed-Action Preparations(R)-2-(3-((benzoxazol-2-yl-d4 (3-(4-methoxyphenoxy-d7)propyl)amino)methyl)phenoxy) butanoic acidTriglyceridesButyratesTabletsHypolipidemic AgentsPhenylalanine

Autor:innen und Institutionen

  • National Center for Geriatrics and Gerontology.
  • Rinku General Medical Center.
  • Kikuchi Medical Association Hospital.
  • Research Center for Health and Sports Sciences, Kumamoto Health Science University.
  • Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine.
  • Global Clinical Development Department, Kowa Company, Ltd.

Zitieren

APA

Arai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Yamasaki, S., Suganami, H., & Ishibashi, S. (2024). Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial. Journal of Atherosclerosis and Thrombosis. https://doi.org/10.5551/jat.64677

Vancouver

Arai H, Yamashita S, Araki E, Yokote K, Tanigawa R, Saito A, et al. Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial. Journal of Atherosclerosis and Thrombosis. 2024. doi:10.5551/jat.64677

BibTeX
@article{Arai2024,
  author = {Arai, Hidenori and Yamashita, Shizuya and Araki, Eiichi and Yokote, Koutaro and Tanigawa, Ryohei and Saito, Ayumi and Yamasaki, Sayumi and Suganami, Hideki and Ishibashi, Shun},
  title = {Efficacy and Safety of Pemafibrate Extended-Release Tablet: a Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Comparison Trial},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2024},
  doi = {10.5551/jat.64677}
}
Kostenlos starten →